BioMarin Completes $4.8bn Amicus Acquisition Adding Two Rare Disease Drugs
BioMarin has completed its $4.8bn acquisition of Amicus Therapeutics at $14.50 per share, adding Galafold and the Pombiliti+Opfolda combination for Fabry and Pompe diseases. The deal also secures US rights to the Phase III FSGS candidate DMX-200, broadening BioMarin’s rare disease portfolio.
1. Acquisition and Terms
BioMarin finalized the acquisition of Amicus Therapeutics for $14.50 per share in an all-cash transaction totalling nearly $4.8bn in equity value. The deal, first announced in December 2025, expands BioMarin’s footprint in lysosomal storage diseases.
2. Expanded Rare Disease Portfolio
The transaction adds Galafold (migalastat) for Fabry disease and the Pombiliti (cipaglucosidase alfa-atga) plus Opfolda (miglustat) regimen for late-onset Pompe disease, both already approved in multiple major markets.
3. Pipeline Diversification with DMX-200
BioMarin also gained US rights to DMX-200, an oral small molecule for focal segmental glomerulosclerosis currently in Phase III trials, enhancing its mid-stage pipeline and long-term growth prospects.